These findings align with the cumulative evidence suggesting that enhanced Th1, CD8+, and NK cell infiltration into tumors is correlated with better prognosis and improved responsiveness to immunotherapies in CRC [43,44]. The gene discussed is CD8A; the disease is colorectal carcinoma.